Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 15/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.32 |
| ▸ | NOS2 | P35228 | 2/20 | 0.32 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18315116 | 0.81 | KLKB1 (0.35) | PDE10ANOS3NOS1NOS2 | |
| SCHEMBL17236176 | 0.78 | PDE10A (0.37) | PDE10ATAAR1NOS3NOS1NOS2 | |
| SCHEMBL22029016 | 0.78 | PDE10A (0.33) | PDE10ATAAR1 | |
| Hydrochloric Acid SCHEMBL17225047 | 0.76 | PDE10A (0.36) | PDE10ATAAR1NOS3NOS1NOS2 | |
| SCHEMBL3637109 | 0.71 | NOS3 (0.41) | PDE10ANOS3NOS1NOS2 | |
| SCHEMBL31314110 | 0.71 | TDP1 (0.35) | PDE10ATAAR1 | |
| SCHEMBL21355574 | 0.71 | TAAR1 (0.38) | PDE10ATAAR1NOS3NOS1NOS2 | |
| SCHEMBL17225037 | 0.70 | ALOX5AP (0.35) | NOS3NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL17225005 | 0.69 | ALOX5AP (0.34) | NOS3NOS1NOS2 | |
| SCHEMBL21586420 | 0.69 | PDE10A (0.38) | PDE10ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236068-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210230142-A9 | FUSED RING COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-07-29 | — | — | US | disclosed |
| US-20200181118-A1 | FUSED RING COMPOUNDS | GENENTECH INC (US) | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230142-A9 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | PDE10A 4280/4885TAAR1 4588/4885NOS3 3408/4885 |
| US-20200181118-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | PDE10A 4280/4885TAAR1 4588/4885NOS3 3408/4885 |
| US-11236068-B2 | Fused ring compounds | KRAS, NRAS, HRAS | PDE10A 4280/4885TAAR1 4588/4885NOS3 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.